DK3083627T3 - [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis - Google Patents

[1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis Download PDF

Info

Publication number: DK3083627T3
Authority: DK; Denmark
Prior art keywords: proteasomin; protozoic; leishmaniasis; triazol; inhibitors
Prior art date: 2013-12-19

Application number

DK14825046.7T

Other languages

English (en)

Inventor

Agnes Biggart

Fang Liang

Casey Jacob Nelson Mathison

Valentina Molteni

Advait Suresh Nagle

Frantisek Supek

Vince Yeh

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-19

Filing date

2014-12-18

Publication date

2019-01-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52302387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3083627(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-18 Application filed by Novartis Ag filed Critical Novartis Ag

2019-01-02 Application granted granted Critical

2019-01-02 Publication of DK3083627T3 publication Critical patent/DK3083627T3/da

Links

NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 title 1
208000004554 Leishmaniasis Diseases 0.000 title 1
208000030852 Parasitic disease Diseases 0.000 title 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

DK14825046.7T 2013-12-19 2014-12-18 [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis DK3083627T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361918089P	2013-12-19	2013-12-19
PCT/US2014/071077 WO2015095477A1 (en)	2013-12-19	2014-12-18	[1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis

Publications (1)

Publication Number	Publication Date
DK3083627T3 true DK3083627T3 (da)	2019-01-02

Family

ID=52302387

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14825046.7T DK3083627T3 (da)	2013-12-19	2014-12-18	[1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis

Country Status (41)

Country	Link
US (6)	US9303034B2 (da)
EP (1)	EP3083627B1 (da)
JP (1)	JP6392352B2 (da)
KR (1)	KR102354082B1 (da)
CN (1)	CN106029666B (da)
AP (1)	AP2016009329A0 (da)
AR (1)	AR098844A1 (da)
AU (1)	AU2014364565B2 (da)
BR (1)	BR112016014004B1 (da)
CA (1)	CA2932870C (da)
CL (1)	CL2016001421A1 (da)
CR (1)	CR20160334A (da)
CU (1)	CU24379B1 (da)
CY (1)	CY1121060T1 (da)
DK (1)	DK3083627T3 (da)
EA (1)	EA030823B1 (da)
EC (1)	ECSP16067921A (da)
ES (1)	ES2701087T3 (da)
GT (1)	GT201600131A (da)
HR (1)	HRP20182021T1 (da)
HU (1)	HUE040254T2 (da)
IL (1)	IL246034B (da)
LT (1)	LT3083627T (da)
MA (1)	MA39186A1 (da)
MX (1)	MX368072B (da)
MY (1)	MY175865A (da)
NZ (1)	NZ721650A (da)
PE (1)	PE20160865A1 (da)
PH (1)	PH12016501198A1 (da)
PL (1)	PL3083627T3 (da)
PT (1)	PT3083627T (da)
RS (1)	RS58053B1 (da)
SG (1)	SG11201604618TA (da)
SI (1)	SI3083627T1 (da)
SV (1)	SV2016005226A (da)
TN (1)	TN2016000253A1 (da)
TW (1)	TWI674263B (da)
UA (1)	UA117046C2 (da)
UY (1)	UY35903A (da)
WO (1)	WO2015095477A1 (da)
ZA (1)	ZA201604415B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112017025668A2 (pt)	2015-05-29	2018-08-07	Glaxosmithkline Ip Dev Ltd	derivados de imidazo [1,2-b] [1,2,4] triazina como agentes antiparasitários
US10479792B2 (en) *	2015-08-07	2019-11-19	GiaxoSmithKline Intellectual Property Development Limited	Compounds
WO2017127627A1 (en)	2016-01-21	2017-07-27	The University Of North Carolina At Chapel Hill	Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
EP4480946A1 (en)	2017-03-27	2024-12-25	Hydro-Québec	Salts for use in electrolyte compositions or as electrode additives
JOP20190278A1 (ar) *	2017-05-31	2019-11-28	Novartis Ag	مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) *	2017-11-06	2022-01-13	Новартис Аг	5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
TW202028208A (zh) *	2018-10-09	2020-08-01	瑞士商諾華公司	N-(4-氟-3-(6-(3-甲基吡啶-2-基)-[1,2,4]三唑并[1,5-a]嘧啶-2-基)苯基)-2,4-二甲基㗁唑-5-甲醯胺固體形式

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4038396A (en)	1975-02-24	1977-07-26	Merck & Co., Inc.	Anti-inflammatory oxazole[4,5-b]pyridines
DE3130633A1 (de) *	1981-08-01	1983-02-17	Basf Ag, 6700 Ludwigshafen	7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3224512A1 (de)	1982-07-01	1984-01-05	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
FR2643903A1 (fr)	1989-03-03	1990-09-07	Union Pharma Scient Appl	Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
FR2652085A1 (fr)	1989-09-20	1991-03-22	Science Organisation	Nouveau procede de synthese de derives d'oxazolopyridines.
DE4129603A1 (de)	1991-09-06	1993-03-11	Thomae Gmbh Dr K	Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0643588A (ja) *	1992-07-27	1994-02-18	Fuji Photo Film Co Ltd	ハロゲン化銀カラー写真感光材料
DE4304650A1 (de)	1993-02-16	1994-08-18	Thomae Gmbh Dr K	Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5496826A (en)	1994-09-02	1996-03-05	Bristol-Myers Squibb Company	Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
JP3735741B2 (ja) *	1995-11-24	2006-01-18	株式会社大塚製薬工場	縮環ピリミジン誘導体
EP0927167A1 (en)	1996-08-14	1999-07-07	Warner-Lambert Company	2-phenyl benzimidazole derivatives as mcp-1 antagonists
AU4499697A (en)	1996-09-13	1998-04-02	New York University	Method for treating parasitic diseases with proteasome inhibitors
WO2001070743A1 (en)	2000-03-20	2001-09-27	Axys Pharmaceuticals, Inc.	Non-amidine containing protease inhibitors
CA2412462A1 (en)	2000-06-14	2001-12-20	Warner-Lambert Company	6,5-fused bicyclic heterocycles
AU2002216649A1 (en)	2000-10-31	2002-05-15	Lynn Bonham	Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002214505A1 (en)	2000-11-09	2002-05-21	Biovitrum Ab	New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
JP2004523490A (ja)	2000-11-28	2004-08-05	ギルフォードファーマシュウティカルズインコーポレイテッド	二置換カルボサイクリックサイクロフィリン結合化合物とその用途
GB0106953D0 (en)	2001-03-20	2001-05-09	Univ Aberdeen	Neufofibrillary labels
NZ530580A (en)	2001-07-27	2007-02-23	Curis Inc	Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7488598B2 (en)	2001-10-26	2009-02-10	Cornell Center For Technology Enterprise And Commercialization	Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CN100338040C (zh)	2001-11-16	2007-09-19	日本化学医药株式会社	黄嘌呤氧化酶抑制化合物
AU2002349477A1 (en)	2001-11-26	2003-06-10	Takeda Chemical Industries, Ltd.	Bicyclic derivative, process for producing the same, and use
TWI276631B (en)	2002-09-12	2007-03-21	Avanir Pharmaceuticals	Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
CA2514733A1 (en)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005014598A1 (en)	2003-07-30	2005-02-17	Laboratorios S.A.L.V.A.T., S.A.	Substituted imidazopyrimidines for the prevention and treatment of cancer
AU2004263190A1 (en)	2003-08-08	2005-02-17	Avanir Pharmaceuticals	Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
MXPA06002853A (es)	2003-09-11	2006-06-14	Kemia Inc	Inhibidores citoquina.
WO2005030206A1 (en)	2003-09-24	2005-04-07	Imclone Systems Incorporated	Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
AU2005220882A1 (en)	2004-03-08	2005-09-22	Georgia State University Research Foundation, Inc	Novel dicationic imidazo(1,2-a)pyridines and 5,6,7,8-tetrahydro-imidazo(1,2a)pyridines as antiprotozoal agents
CN101087787A (zh)	2004-12-23	2007-12-12	霍夫曼-拉罗奇有限公司	苯甲酰胺衍生物，它们的制备及作为药剂的应用
EP1831218A2 (en)	2004-12-23	2007-09-12	F.Hoffmann-La Roche Ag	Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
WO2006101456A1 (en)	2005-03-21	2006-09-28	S*Bio Pte Ltd	Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
EP1919910B1 (en)	2005-07-29	2011-02-23	F. Hoffmann-La Roche AG	Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
CN101208339B (zh)	2005-08-01	2010-12-29	霍夫曼-拉罗奇有限公司	杂环苄基氨基衍生物，它们的制备以及作为药剂的应用
EP1909910A1 (en)	2005-08-04	2008-04-16	Sirtris Pharmaceuticals, Inc.	Benzimidazole derivatives as sirtuin modulators
JP2007063225A (ja)	2005-09-01	2007-03-15	Takeda Chem Ind Ltd	イミダゾピリジン化合物
US7438916B2 (en)	2005-10-14	2008-10-21	Virginia Tech Intellectual Properties, Inc.	Therapeutic target for protozoal diseases
US7700616B2 (en)	2006-05-08	2010-04-20	Molecular Neuroimaging, Llc.	Compounds and amyloid probes thereof for therapeutic and imaging uses
CN101490037B (zh)	2006-07-11	2013-06-12	大熊制药株式会社	联芳基苯并咪唑衍生物以及包含该衍生物的药物组合物
PE20080906A1 (es)	2006-08-17	2008-07-05	Kemia Inc	Derivados heteroarilo como inhibidores de citocina
PE20080888A1 (es)	2006-10-18	2008-08-26	Novartis Ag	COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008100376A2 (en)	2007-02-15	2008-08-21	Sirtris Pharmaceuticals, Inc.	Truncation variants of sirt1 and methods of use thereof
US20090131481A1 (en)	2007-03-27	2009-05-21	Paratek Pharmaceuticals, Inc.	Transcription Factor Modulating Compounds and Methods of Use Thereof
AR068072A1 (es)	2007-04-19	2009-11-04	Novartis Ag	Derivados de bencimidazoles, composiciones farmaceuticas y usos
WO2009005675A1 (en)	2007-06-28	2009-01-08	Abbott Laboratories	Novel triazolopyridazines
CL2008001933A1 (es)	2007-06-29	2009-09-25	Millennium Pharm Inc	Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
TW200932872A (en)	2007-10-17	2009-08-01	Cheil Ind Inc	Novel compound for organic photoelectric device and organic photoelectric device including the same
RU2364597C1 (ru)	2007-12-14	2009-08-20	Андрей Александрович Иващенко	ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
US8642660B2 (en)	2007-12-21	2014-02-04	The University Of Rochester	Method for altering the lifespan of eukaryotic organisms
WO2009112445A1 (en)	2008-03-10	2009-09-17	Novartis Ag	Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US20100168084A1 (en)	2008-05-08	2010-07-01	Huber L Julie	Therapeutic compounds and related methods of use
WO2009151546A2 (en)	2008-05-27	2009-12-17	Ptc Therapeutics, Inc.	Methods for treating spinal muscular atrophy
CA2733533C (en)	2008-08-25	2013-12-17	Irm Llc	Hedgehog pathway modulators
US8691187B2 (en)	2009-03-23	2014-04-08	Eli Lilly And Company	Imaging agents for detecting neurological disorders
JO3156B1 (ar) *	2009-07-09	2017-09-20	Novartis Ag	ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
US20120157471A1 (en)	2009-09-01	2012-06-21	Pfizer Inc.	Benzimidazole derivatives
ME02020B (me) *	2009-09-29	2015-05-20	Univ Texas	Anti-malarijski agensi kao inhibitori dihidroorotat dehidrogenaze
EP3138838A1 (en) *	2010-01-29	2017-03-08	Dana-Farber Cancer Institute, Inc.	Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
US20130150351A1 (en)	2010-06-03	2013-06-13	Stanley T. Carmichael	Methods and compositions for treating a subject for central nervous system (cns) injury
TWI617559B (zh)	2010-12-22	2018-03-11	江蘇恆瑞醫藥股份有限公司	２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
US9206164B2 (en)	2011-03-25	2015-12-08	Boehringer Ingelheim International Gmbh	Pyrazole compounds as CRTH2 antagonists
WO2013009827A1 (en)	2011-07-13	2013-01-17	Tempero Pharmaceuticals, Inc.	Methods of treatment
GB201114051D0 (en)	2011-08-15	2011-09-28	Domainex Ltd	Compounds and their uses
ES2665580T3 (es)	2011-11-11	2018-04-26	Gilead Apollo, Llc	Inhibidores de ACC y usos de los mismos
WO2013078254A1 (en)	2011-11-22	2013-05-30	Array Biopharma Inc.	Bicyclic heteroaryl derivatives as kinase inhibitors
JP6049768B2 (ja) *	2012-03-07	2016-12-21	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	トリアゾロピラジン誘導体
GB201205669D0 (en)	2012-03-30	2012-05-16	Agency Science Tech & Res	Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
AR091586A1 (es)	2012-06-28	2015-02-11	Fujifilm Corp	Derivado de amida o su sal como inhibidor de la produccion de colageno
CN103570625A (zh)	2012-07-19	2014-02-12	南京英派药业有限公司	N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
DK2888251T3 (da)	2012-08-21	2019-07-29	Peter Maccallum Cancer Inst	Perforinhæmmende benzensulfonamidforbindelser, fremstilling og anvendelser deraf
UY35400A (es) *	2013-03-15	2014-10-31	Novartis Ag	Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9233961B2 (en)	2013-03-15	2016-01-12	Novartis Ag	Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en)	2013-03-15	2016-03-29	Novartis Ag	Compounds and compositions for the treatment of parasitic diseases
WO2014151729A1 (en)	2013-03-15	2014-09-25	Irm Llc	Compounds and compositions for the treatment of parasitic diseases

2014
- 2014-12-18 MY MYPI2016702061A patent/MY175865A/en unknown
- 2014-12-18 EP EP14825046.7A patent/EP3083627B1/en active Active
- 2014-12-18 KR KR1020167019388A patent/KR102354082B1/ko not_active Expired - Fee Related
- 2014-12-18 AU AU2014364565A patent/AU2014364565B2/en active Active
- 2014-12-18 SG SG11201604618TA patent/SG11201604618TA/en unknown
- 2014-12-18 JP JP2016541014A patent/JP6392352B2/ja active Active
- 2014-12-18 CA CA2932870A patent/CA2932870C/en active Active
- 2014-12-18 TN TN2016000253A patent/TN2016000253A1/en unknown
- 2014-12-18 UA UAA201607112A patent/UA117046C2/uk unknown
- 2014-12-18 US US14/574,775 patent/US9303034B2/en active Active
- 2014-12-18 MX MX2016008079A patent/MX368072B/es active IP Right Grant
- 2014-12-18 BR BR112016014004-4A patent/BR112016014004B1/pt active IP Right Grant
- 2014-12-18 HR HRP20182021TT patent/HRP20182021T1/hr unknown
- 2014-12-18 CN CN201480075574.3A patent/CN106029666B/zh active Active
- 2014-12-18 MA MA39186A patent/MA39186A1/fr unknown
- 2014-12-18 HU HUE14825046A patent/HUE040254T2/hu unknown
- 2014-12-18 EA EA201691271A patent/EA030823B1/ru not_active IP Right Cessation
- 2014-12-18 PE PE2016000831A patent/PE20160865A1/es active IP Right Grant
- 2014-12-18 PT PT14825046T patent/PT3083627T/pt unknown
- 2014-12-18 DK DK14825046.7T patent/DK3083627T3/da active
- 2014-12-18 RS RS20181477A patent/RS58053B1/sr unknown
- 2014-12-18 NZ NZ721650A patent/NZ721650A/en not_active IP Right Cessation
- 2014-12-18 TW TW103144389A patent/TWI674263B/zh not_active IP Right Cessation
- 2014-12-18 ES ES14825046T patent/ES2701087T3/es active Active
- 2014-12-18 LT LTEP14825046.7T patent/LT3083627T/lt unknown
- 2014-12-18 CR CR20160334A patent/CR20160334A/es unknown
- 2014-12-18 AP AP2016009329A patent/AP2016009329A0/en unknown
- 2014-12-18 CU CU2016000090A patent/CU24379B1/es unknown
- 2014-12-18 PL PL14825046T patent/PL3083627T3/pl unknown
- 2014-12-18 WO PCT/US2014/071077 patent/WO2015095477A1/en not_active Ceased
- 2014-12-18 SI SI201430990T patent/SI3083627T1/sl unknown
- 2014-12-19 UY UY0001035903A patent/UY35903A/es not_active Application Discontinuation
- 2014-12-19 AR ARP140104775A patent/AR098844A1/es active IP Right Grant
2016
- 2016-02-23 US US15/051,446 patent/US9700559B2/en active Active
- 2016-06-05 IL IL246034A patent/IL246034B/en active IP Right Grant
- 2016-06-09 CL CL2016001421A patent/CL2016001421A1/es unknown
- 2016-06-16 SV SV2016005226A patent/SV2016005226A/es unknown
- 2016-06-17 GT GT201600131A patent/GT201600131A/es unknown
- 2016-06-17 PH PH12016501198A patent/PH12016501198A1/en unknown
- 2016-06-29 ZA ZA2016/04415A patent/ZA201604415B/en unknown
- 2016-08-16 EC ECIEPI201667921A patent/ECSP16067921A/es unknown
2017
- 2017-05-19 US US15/600,183 patent/US10085989B2/en active Active
2018
- 2018-08-29 US US16/116,418 patent/US10596175B2/en active Active
- 2018-12-05 CY CY181101300T patent/CY1121060T1/el unknown
2020
- 2020-02-03 US US16/780,628 patent/US11123348B2/en active Active
2021
- 2021-08-10 US US17/398,852 patent/US20210369716A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2932870C (en)	2021-11-09
PE20160865A1 (es)	2016-09-03
US11123348B2 (en)	2021-09-21
UY35903A (es)	2015-07-31
IL246034B (en)	2020-02-27
EA030823B1 (ru)	2018-10-31
JP2017501177A (ja)	2017-01-12
US9303034B2 (en)	2016-04-05
US20170333437A1 (en)	2017-11-23
ZA201604415B (en)	2017-09-27
EP3083627B1 (en)	2018-09-05
IL246034A0 (en)	2016-08-02
AU2014364565A1 (en)	2016-07-14
PH12016501198A1 (en)	2016-08-15
TWI674263B (zh)	2019-10-11
US20200179391A1 (en)	2020-06-11
KR102354082B1 (ko)	2022-01-24
LT3083627T (lt)	2018-12-27
SG11201604618TA (en)	2016-07-28
JP6392352B2 (ja)	2018-09-19
CR20160334A (es)	2016-12-06
US20210369716A1 (en)	2021-12-02
US10596175B2 (en)	2020-03-24
US9700559B2 (en)	2017-07-11
AP2016009329A0 (en)	2016-07-31
CA2932870A1 (en)	2015-06-25
NZ721650A (en)	2018-12-21
BR112016014004B1 (pt)	2022-11-01
MY175865A (en)	2020-07-14
US10085989B2 (en)	2018-10-02
CN106029666A (zh)	2016-10-12
BR112016014004A2 (da)	2017-08-08
HUE040254T2 (hu)	2019-02-28
EP3083627A1 (en)	2016-10-26
CN106029666B (zh)	2018-05-18
US20160303129A1 (en)	2016-10-20
PT3083627T (pt)	2018-11-30
CY1121060T1 (el)	2019-12-11
KR20160093077A (ko)	2016-08-05
TN2016000253A1 (en)	2017-10-06
AU2014364565B2 (en)	2017-06-15
ECSP16067921A (es)	2017-10-31
US20150175613A1 (en)	2015-06-25
SV2016005226A (es)	2019-04-23
CL2016001421A1 (es)	2016-12-30
RS58053B1 (sr)	2019-02-28
WO2015095477A1 (en)	2015-06-25
AR098844A1 (es)	2016-06-15
GT201600131A (es)	2018-12-18
UA117046C2 (uk)	2018-06-11
CU20160090A7 (es)	2017-05-10
CU24379B1 (es)	2019-02-04
ES2701087T3 (es)	2019-02-20
MX2016008079A (es)	2016-09-16
MA39186A1 (fr)	2017-11-30
MX368072B (es)	2019-09-18
US20190000852A1 (en)	2019-01-03
SI3083627T1 (sl)	2019-01-31
HRP20182021T1 (hr)	2019-01-25
TW201609734A (zh)	2016-03-16
EA201691271A1 (ru)	2016-12-30
PL3083627T3 (pl)	2019-02-28

Publication	Publication Date	Title
CY2022003I2 (el)	2022-03-24	Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
DK3418281T3 (da)	2020-12-07	Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
PH12019501321A1 (en)	2020-10-12	Methods of treating or preventing cholesterol related disorders
DK3523301T3 (da)	2020-08-03	Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3523302T3 (da)	2022-08-01	Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
HUE053067T2 (hu)	2021-06-28	Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
DK3077397T3 (da)	2019-12-16	2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
DK3324977T3 (da)	2022-10-17	Benzodiazepinderivater som rsv-inhibitorer
NI201800042A (es)	2018-06-21	Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
BR112014028395A2 (pt)	2017-06-27	derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
EP3030323A4 (en)	2017-01-11	Kdm1a inhibitors for the treatment of disease
DK3419978T3 (da)	2020-06-02	Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
EA201591420A1 (ru)	2016-02-29	Гетероарильные соединения и их применение
DK3019496T3 (da)	2019-12-09	Pyrimidinderivater som kinaseinhibitorer
EA201491456A1 (ru)	2014-12-30	Соединения-ингибиторы raf
CL2015002635A1 (es)	2016-02-19	Compuestos y composiciones para el tratamiento de enfermedades parasitarias
DK3134413T3 (da)	2019-10-14	Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
LT3590928T (lt)	2021-08-25	Pirimidino dariniai, skirti virusinės infekcijos gydymui
DK3380471T3 (da)	2021-10-11	Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser
CL2016000496A1 (es)	2016-10-07	Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
ZA201604415B (en)	2017-09-27	[1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
EP3508487A4 (en)	2020-03-18	PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND
DK3578562T3 (da)	2021-07-12	L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
EP3551630A4 (en)	2020-07-15	IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
DK3679042T3 (da)	2023-05-01	Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer